People buying a medicinal marijuana extract over the internet often don’t get what they paid for, a new study warns. Nearly 7 out of 10 cannabidiol (CBD) products tested did not contain the amount of marijuana extract promised on the label, researchers report. “We wanted to see if they are accurately describing what is in their product,” said lead researcher Marcel Bonn-Miller. “We found that generally speaking, no, they’re not. There are some people that are doing it right, but the majority of people in the industry are not,” said Bonn-Miller. He is an adjunct assistant professor of psychology in psychiatry at the University of Pennsylvania School of Medicine.
A CBD-based pharmaceutical drug in development is one more step closer to potential FDA approval. Earlier this week, London-based GW Pharmaceuticals plc, which operates in the United States as Greenwich Biosciences, wrapped up its New Drug Application for Epidiolex, a formulation of the cannabis compound cannabidiol (CBD) for the treatment of seizures associated with two specific types of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.
It’s a buzzy trend in the wellness world, and while CBD is one of the compounds found in the cannabis plant, don’t worry — it won’t get you high. Here’s what you need to know about the latest ingredient everyone’s talking about. What is CBD? CBD is the abbreviation for cannabidiol, one of the many cannabinoids, or chemical compounds, found in marijuana and hemp. You’re probably already familiar with THC, which is another compound found in the cannabis plant. But unlike THC, CBD is not psychoactive. In other words, it’s not what gets you stoned. It’s also different from medical marijuana, which has been shown to reduce pain.
The parents of a 20-month-old girl say Indiana child welfare authorities threatened to take the child away from them because they chose to treat her epilepsy with a legal cannabis extract. Lelah Jerger, the child’s mother, said personnel at Riley Hospital for Children reported her to Indiana’s Child Protective Services after she and her husband decided to use cannabidiol oil, or CBD, to treat their daughter Jaelah, rather than use the medication prescribed by a Riley doctor.
Cell-sized cannabis factories could soon be producing medical treatments for epilepsy. A non-psychoactive compound found in marijuana plants called cannabidivarin (CBDV) has shown promise in the treatment of severe cases of epilepsy. However, to treat just 10 per cent of people with epilepsy would require around 1500 tonnes (tons) of pure CBDV. To obtain this amount using current methods, you would need to plant large quantities of marijuana and extract their small supply of CBDV. “There’s so little of this chemical in plants it would actually be impossible to harvest it by traditional means,” says Kevin Chen, who runs Hyasynth Bio, a start-up in Montreal, Canada.
Medical marijuana appears to hold only limited promise for sick children and teenagers, a new review suggests. It can help kids fighting cancer with chemotherapy-related nausea and vomiting, and it can control seizures somewhat in children with epilepsy, said study author Dr. Shane Shucheng Wong. He is a psychiatrist with Massachusetts General Hospital, in Boston. But there’s not enough evidence to say that medical marijuana can help kids with any other medical conditions, such as neuropathic pain, post-traumatic stress disorder (PTSD) or Tourette’s syndrome, Wong added.
Could endocannabinoids be the key to reducing seizures? Boosting our own natural marijuana – known as endocannabinoids – is safer than using cannabis to block epileptic seizures, a group of University of Malta researchers have found.
Treatment with cannabidiol reduces some major symptoms in mice with a genetic condition recapitulating Dravet syndrome, a devastating childhood brain disorder. Cannabidiol is a non-intoxicating substance among the several active compounds derived from Cannabis plants. This molecule can also be produced synthetically. The results of its use to treat Dravet syndrome are reported in the latest edition of the Proceedings of the National Academy of Sciences, PNAS.
Zynerba Pharmaceuticals has reported that its cannabis-based epilepsy gel ZYN002 (cannabidiol [CBD] gel) has failed to meet the primary point in a phase 2 clinical trial. The trial dubbed as STAR 1 was held in 188 adult epilepsy patients with focal seizures across 14 sites in Australia and New Zealand. When compared to placebo, ZYN002 during the treatment period could not show a statistically significant decrease in focal seizures in comparison to the baseline period for either the high or low dose cohorts. STAR expands to Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy. The patients in the phase 2 trial were randomized to be treated during a 12-week period for every 12 hours with either 195mg of ZYN002 4.2% CBD gel, 97.5mg of ZYN002 4.2% CBD gel or placebo gel. The primary...
New research published in Epilepsia, a journal of the International League Against Epilepsy (ILAE), suggests that an investigational neurological treatment derived from cannabis may alter the blood levels of commonly used anti-epileptic drugs. It is important for clinicians to consider such drug interactions during treatment of complex conditions.
A component of marijuana called cannabidiol eased seizures in children with Dravet syndrome, a potentially fatal form of epilepsy, in a late-stage clinical trial1. Dravet syndrome stems from mutations in sodium channels, most often in a gene called SCN1A. A gene in the same family, SCN2A, is a top autism candidate. About one in four children with Dravet syndrome also has an autism diagnosis. Many children with Dravet syndrome take multiple epilepsy drugs to control their severe seizures. But some children do not respond to the drugs. Some parents of children with Dravet syndrome or autism turn to marijuana, based purely on anecdotal evidence. The new study is the first rigorous trial to show that purified cannabidiol decreases seizures in children with epilepsy. “It’s a huge milestone,” sa...
Epilepsy is a disease that disrupts the electrical activity of the nervous system, causing seizures. More than 65 million people in the world have epilepsy. 1 in 26 Americans will develop the disease during their lives. Children are the group most frequently diagnosed with new cases of epilepsy. In the United States, 300,000 children under 14 are affected by the condition. Some may outgrow the disorder, but most will not. The number of senior citizens with epilepsy is also 300,000. People with epilepsy have a range of treatment options, including alternative therapies. The illness is a complex condition, however, and all alternative treatment options must be looked at carefully, to ensure they are effective. Causes of epilepsy Epilepsy is a complex disease that can disrupt the electrical a...